Impressive Clinical Results For Argenx’s Oncology Candidate Seal The Deal for Janssen
Janssen boosts its oncology pipeline with argenx’s novel anti-CD70 antibody, which has potential in a variety of indications.
You may also be interested in...
The two flagship firms of the European biotech scene are pooling their technologies to jointly discover, develop and commercialize drugs against cancer and autoimmune diseases.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.